Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00611598 · ClinicalTrials.gov registry record
DNA Repair and Genetic Susceptibility to Lung Cancer
A clinical trial of Lung Cancer and Single Primary Lung Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 218
- Enrollment target
- 1
- Study location
NCT00611598: Completed study of Lung Cancer and Single Primary Lung Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00611598 is a study of Lung Cancer and Single Primary Lung Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 218 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00611598, a study of Lung Cancer and Single Primary Lung Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 218 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to help us better understand the cellular changes that may lead to the development of lung cancer. We want to compare people with a second primary lung cancer with those who have only a first primary lung cancer. We hope to use the information obtained in this study as the basis for future studies and will not regard the results from this study as final. We will analyze your blood cells and DNA to measure the changes in several genes that we believe may be involved in lung cancer. We also want to evaluate the capacity for your DNA to repair itself.
Conditions Studied
Interventions
- OTHER Blood draw and Questionnaires
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2003-02-11 |
| Est. Completion | 2023-03-24 |
What the finished NCT00611598 record still lists
NCT00611598 is an observational study that tracks outcomes without assigning an intervention. The registered 218 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (77% lower).
The record links to 3 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Blood draw and Questionnaires is the first listed.
NCT00611598 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00611598 about?
NCT00611598 is a clinical study titled "DNA Repair and Genetic Susceptibility to Lung Cancer". The purpose of this study is to help us better understand the cellular changes that may lead to the development of lung cancer. We want to compare people with a second primary lung cancer with those who have only a first primary lung cancer. We hope to use the information obtained in this study as t...
What is the current status of trial NCT00611598?
This trial is currently completed. The enrollment target is 218 participants. The study started on 2003-02-11. Estimated completion is 2023-03-24.
What conditions does trial NCT00611598 study?
This clinical trial studies the following conditions: Lung Cancer, Single Primary Lung Cancer, Second Primary Lung Cancer.
What interventions are being tested in trial NCT00611598?
The interventions under investigation include: Blood draw and Questionnaires (OTHER).
Who is sponsoring clinical trial NCT00611598?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00611598 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00611598's enrollment target sits among peer trials
218 125th of 409 higher than 285 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04693858 · 218 participants · NA
Efficacy Trial of the CALM Intervention
- NCT05909202 · 218 participants · NA
A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
- NCT06000761 · 218 participants · NA
Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit
- NCT06249126 · 218 participants · NA
Primary Subtalar Arthrodesis for Calcaneal Fractures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI